- Open Access
The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy
- Yan Wang†1, 4,
- Ziliang Wang†1, 4,
- Zihao Qi1, 4,
- Sheng Yin2, 4,
- Na Zhang1, 4,
- Yang Liu2, 4,
- Mingming Liu1, 4,
- Jiao Meng1, 4,
- Rongyu Zang2, 4Email author,
- Zhen Zhang3, 4Email author and
- Gong Yang1, 4, 5Email author
© Wang et al.; licensee BioMed Central Ltd. 2014
Received: 10 September 2013
Accepted: 16 April 2014
Published: 28 April 2014
It is well known that the activation of Aurora A/B (Aur A/B) or inactivation of BRCA1/2 induces tumor formation. Others and we have reported that the mutual suppression between Aur A/B and BRCA1/2 may manipulate cancer cell growth and tumorigenesis, however, the interactive regulation and mechanism between these molecules are still elusive. In this study, by consecutive silencing of Aur A/B or/and BRCA1/2 with specific shRNAs, we showed that, in BRCA2-deficient pancreatic cancer cell line Capan-1 and in ovarian cancer cell line OVCA433, Aur A/B and BRCA1/2 inversely regulated the expression of each other likely through proteasome-mediated proteolysis but not through gene transcription. Aur A/B and BRCA1/2 conversely regulated cell cycle progression mainly through control of p53 and cyclin A. Moreover, the disruption of Aur A/B blocked abnormal cytokinesis and decreased cell multinuclearity and chromosome tetraploidy, whereas the deprivation of BRCA1/2 promoted the abnormal cytokinesis and enhanced the cell multinuclearity and tetraploidy. Furthermore, we showed by animal assays that the depletion of Aur A/B inhibited tumor growth of both cell lines, while the knockdown of BRCA1/2 promoted the tumor growth. However, the concurrent silencing of Aur A/B and BRCA1/2 diminished the effects of these molecules on the regulation of cell cycle, cytokinesis, and tetraploidy, leading to the burdened tumor sizes similar to those induced by scrambled shRNA-treated control cells. In summary, our study revealed that the negative interplay between Aur A/B and BRCA1/2 inversely controls the cell proliferation, cell cycle progression, cell multinuclearity, and tetraploidization to modulate tumorigenesis.
In Aurora kinase family, Aurora A and Aurora B (simplified as Aur A and Aur B) are mostly studied members functioning as serine/threonine kinases regulating centrosome maturation, mitotic spindle assembly, and chromosome segregation . It has been reported that the overexpression or amplification of Aur A/B drives chromosomal instability and induces tumor formation. Studies have shown that both Aur A and Aur B promote cell cycle progression [2, 3]. Aur A is involved in cytokinesis, and overexpression of Aur A promotes abnormal cytokinesis and increases the number of polyploid cells [2, 4]. Other studies suggest that the inactivation of Aur B promotes the completion of cytokinesis through abscission and prevents against tetraploidization .
Breast cancer susceptibility genes 1 and 2 (BRCA1/2) are known as tumor suppressor genes playing critical roles in DNA repair, cell cycle checkpoint control, and in maintenance of the genomic stability. Both BRCA1 and BRCA2 suppress the cell cycle progression [6–8]. Cancer cells in tissues of BRCA1 or BRCA2 mutation carriers are usually near tetraploid/polyploidy [9, 10]. In mammary epithelial cells, blocking BRCA1 function leads to the aberrant mitosis with binuclear and tetraploidy . Likewise, in murine embryo fibroblasts and cervical cancer cells, the absence of BRCA2 impairs the completion of cell division due to abnormal cytokinesis, leading to chromosomal polyploidization .
Increasing evidences have suggested that Aur A/B and BRCA1/2 may interplay to control the cell cycle, chromosome polyploidy, and tumorigenesis. For examples, Aur A physically binds to and phosphorylates BRCA1 at Ser308, leading to the abrogation of G2-M checkpoint , while BRCA1 can in return inhibit the activity of Aur A kinase through Gadd45a . We have recently reported that Aur A and BRCA2 are mutually suppressed in ovarian cancer cells to control the RAS-associated genomic instability and tumorigenesis through the regulation of the cytokinesis and polyploidization . Another study showed that the overexpression of BRCA2 in breast cancer cells suppresses the Aur A/B expression and reduces the number of polyploid cells . Thus, Aur A/B and BRCA1/2 may interactively control the cell cycle progression, cytokinesis, polyploidization, and tumorigenesis. However, such an interactive regulation between Aur A/B and BRCA1/2 remains to be illustrated.
In this study, to explore novel interactive insights between Aur A/B and BRCA1/2, we used specific shRNAs to consecutively silence the expressions of Aur A/B and BRCA1/2 in pancreatic and ovarian cancer cell lines, and analyzed the cell proliferation, cell cycle progression, cytokinesis, chromosomal polyploidy, and tumorigenesis of resulting cells. Our results revealed that Aur A/B and BRCA1/2 are interactively suppressed to control the cancer cell growth and tumorigenesis through the regulation of the cell cycle progression, cytokinesis, and tetraploidy.
Cell lines and cell culture
Human pancreatic cancer cell line (Capan-1), ovarian epithelial cancer cell line (OVCA433), retroviral packaging cells (Phoenix amphotropic cells) and lentiviral packaging cells (293 T cells) were purchased from American Type Culture Collection (ATCC, America). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco), supplemented with 10% fetal bovine serum, 2 mM l-glutamine, penicillin (100 units/ml), and streptomycin (100 μg/ml). All cells were incubated at 37°C in an atmosphere of 5% CO2 and 95% air.
Plasmids construction and cell transfection or viral infection
To silence the expressions of Aur A, Aur B, BRCA1 and BRCA2, the DNA oligonucleotides used to generate shRNAs against the open reading frames of their corresponding mRNAs were 5′-GUCUUGUGUCCUUCAAAUU-3′(Aur A shRNA), 5′- AGCCAUUUCAUCGUGGCGC-3′(Aur B shRNA), 5′-AAGUACGAGAUUUAGUCCG-3′ (BRCA1 shRNA) and 5′-ACAAUUACGAACCAAACCG-3′ (BRCA2 shRNA). pBabe/U6-neomycin-Aur Ai, pGIPz-puromycin-Aur Bi, pBabe/U6-zeocin-BRCA1i and pBabe/U6-blasticidin-BRCA2i were generated according to the previously reported method . The control vectors were similarly constructed by directly inserting a scrambled shRNA (Scr) into the corresponding vectors .
Viruses from pBabe vectors were generated and harvested as described previously . Viruses from pGIPz-puromycin-Aur Bi were generated using FuGENE 6 (Promega, San Luis Obispo, CA) and harvested according to manufacturer’s instruction. The resulting supernatant was used to infect target cells (Capan-1 and OVCA433) by using a method described before. Briefly, cells were infected twice for a total of 6 days (3 days for each infection) and the positive clones were selected with puromycin (200 ng/mL), neomycin (0.5-2.5 mg/ml), zeocin (100–750 μg/ml), or blasticidin (3–10 μg/ml) for 10–14 days to establish new stable cell lines.
The resulting cell lines were used later for various analyses, including immunoblotting, immunofluorescence and cell cycle.
Real time fluorescence quantitative polymerase chain reaction
To analyze mRNA expression in cells, qRT-PCR analysis was performed as previously described . Briefly, total RNA was isolated with Trizol reagent (Invitrogen, Carlsbad, CA). All RNAs were then reverse transcribed into cDNAs using the ExScript RT-PCR kit (TaKaRa, Japan) following the manufacturer’s instructions. Oligonucleotide primer pairs for Aur A, Aur B, BRCA1, BRCA2 and GAPDH are described in Additional file 1: Table S1. All amplifications and detections were carried out in the Applied Biosystems Prism 7900 system (Applied Biosystems, Foster City, CA) using the ExScript Sybr green QPCR kit (TaKaRa) and the following program: 1 cycle of 30 sec at 95°C followed by 40 cycles of (5 sec at 95°C, 20 sec at 60°C), followed by a 30-min melting curve collection, which was used to verify the primer dimers. Statistical analyses were performed using the 2-△△CT relative quantification method. The assays were repeated three times in triplicate.
Cell proliferation and colony formation assay
The cell proliferation was measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay. 4 × 103 cells for Capan-1 and 3 × 103 cells for OVCA433 in 200 μl medium were incubated in 96-well culture plates. Cell growth was detected using MTT reagent with Synergy H4 Hybrid Reader. Briefly, the culture medium was removed at 1, 2, 3, 4, 5, 6, and 7 days, and 0.5 mg/ml MTT in 200 μl medium was added to each well and incubated for 4 h, followed by treatment with 150 μl of DMSO for 10 min. Data were collected by measuring the absorbance of optical density (OD) at 570 nm and subtracted from the background OD at 490 nm. The assays were repeated three times in triplicate.
For plate colony formation, 250 cells were seeded in 6-well plate. Duplicate cultures of each cell type were maintained at 37°C in a 5% CO2 atmosphere, and fresh medium was fed every 7 days. The number of colonies with >50 cells in each well was counted at 14 to 21 days. The assays were repeated three times.
Cell cycle analysis
Cells (1–2 × 106) were harvested, washed twice with 1 × PBS. The cells were fixed with 4 ml of cold 75% ethanol at −20°C overnight and then washed twice with 1 × PBS. The cells were then resuspended in 500 μl of 1× PBS and stained with 200 μl of propidium iodide (50 μl/ml; Sigma-Aldrich, Missouri, US) and 20 μl of RNase (1 mg/ml; Sigma-Aldrich, Missouri, US) in a 37°C water bath for 15 to 20 minutes. Cell cycles were determined by FAC Station (Beckman Coulter, FV500) and analyzed by using Kaluza® Flow Analysis Software and a published method. The assays were repeated three times.
To analyze protein expression in cells, immunoblotting analysis was performed as previously described . Antibodies against the following proteins were obtained from Santa Cruz Technology (California, US): Aur A (sc-25425), Aur B (sc-25426), BRCA1 (sc-6954), CDK2 (sc-163), CDK4 (sc-260), CDK6 (sc-177), cyclin D1 (sc-718), cyclin E (sc-247), cyclin A (SC-751). Antibodies against BRCA2 (19791-1-AP) and cyclin B1 (cs-4135) were obtained from Proteintech (Chicago, USA) and Cell Signaling Technology (Massachusetts, US), respectively. The detection of β-actin (A2228, Sigma Aldrich, St. Louis, MO) was used as a loading control. The secondary antibodies were F(ab)2 fragments of donkey anti-mouse immunoglobulin or of donkey anti-rabbit immunoglobulin linked to horseradish peroxidase from Cell Signaling Technology (Massachusetts, US). Immunoblotting reagents were from an electrochemiluminescence kit (Amersham Biosciences). To test whether the expression levels of proteins were regulated through proteasome-mediated degradation, cells were exposed with 20 μM MG132 (#S2619, Selleck Company, Texas, America) for 3 h and then harvested for Western blotting analysis.
Immunofluorescence staining was done according to a published protocol . Primary antibodies against Aur A (sc-25425), Aur B (sc-25426), BRCA1 (sc-6954) and BRCA2 (sc-1818) were obtained from Santa Cruz Technology (California, US). DNA dye 4′,6-diamidino-2-phenylindole (DAPI) was obtained from Molecular Probes. The secondary antibodies used were the FITC-conjugated donkey anti-mouse IgG, cy3-conjugated donkey anti-rabbit IgG, Texas red-conjugated or FITC-conjugated donkey anti-goat IgG (Jackson ImmunoResearch Laboratory). All stained cells were examined and photographed with a Leica SP5 confocal fluorescence microscope.
Analysis of metaphase chromosomes
Cells were cultured for 24 h and collected for chromosome preparation using standard procedures. Briefly, cells were exposed to colchicine (0.1 μg/mL for OVCA433 and 0.05 μg/ml for Capan-1) for 3 h, then subjected to hypotonic treatment (0.075 M KCl for 30 min at 37°C) and fixed in a mixture of methanol and acetic acid (3:1). After three changes of the fixative, the chromosome spreads were prepared by dropping the cell suspension onto cold slides, which were then air-dried. The slides were stained with Giemsa and examined for numerical abnormalities in the chromosomes. 3 slides and 30–36 metaphase spreads in each slide were analyzed for each cell line. The assays were repeated three times.
Xenograft tumors in nude mice
To generate tumor growth in vivo, 5 × 106 cells of each cell line were subcutaneously injected into 4- to 6-week-old BALB/c athymic nude mice (Department of Laboratory Animal, Fudan University). The animal experiments were approved by the Institutional Animal Care and Use Committee of Fudan University and performed following Institutional Guidelines and Protocols. Each cell line was bilaterally injected into six mice, for a total of 12 injections. The longest diameter “a” and the shortest diameter “b” of tumors were measured and the tumor volume was calculated with the use of the following formula: tumor volume (in mm3) = a × b2 × 0.52 , where 0.52 is a constant to calculate the volume of an ellipsoid. When a tumor reached 2.0 cm in diameter, the mouse were sacrificed and the tumors were weighed.
Data were statistically analyzed with the Student t test. P < 0.05 was considered statistically significant.
Interactive regulation of Aur A/B and BRCA1/2 in cancer cells
To test whether Aur A/B and BRCA1/2 are regulated with each other through gene transcription, we first performed qRT-PCR to measure the mRNA levels of Aur A/B and BRCA1/2 in all cell lines treated with or without specific shRNAs. As shown in Figure 1C and D, the mRNA of each protein was reduced only in cell lines treated with its specific shRNA, but was not significantly altered in cell lines treated with non-isogenic shRNAs. Thus, these results suggested that the regulation of proteins between Aur A/B and BRCA1/2 might be at the post-translational level other than at the transcriptional level.
Because the proteasome-mediated protein degradation is one of the mostly characterized mechanisms in post-translational modification of many proteins, and increasing literatures have reported that the protein levels of Aur A/B and BRCA1/2 could be controlled via proteasome-mediated proteolysis [18–21], we treated cells with MG132, an inhibitor of the 26S proteasome, to test whether these proteins were essentially regulated through the classic protein degradation. As shown in Figure 1E and F, the inhibition of proteolysis by MG132 almost eliminated the divergences of protein expressions induced by non-isogenic shRNAs in cells, which is consistent with our previous result . To sum up, the negative interplay of Aur A/B and BRCA1/2 proteins may be regulated mainly through proteasome-mediated protein degradation.
Backward regulation of cell proliferation and colony formation by Aur A/B and BRCA1/2
We then detected colony formation ability of various cell lines. Consistent with the proliferation assay, the colony number was reduced after silencing of Aur A and/or B, but was increased after the disruption of BRCA1/2 in both Capan-1 and OVCA433 cells in comparison with scrambled shRNA-treated control cells (Figure 2C-F). Introduction of Aur A and/or B shRNAs into cells along with BRCA1 or/and BRCA2 shRNAs in both pancreatic and ovarian cancer cells evidently reduced the number of colonies, compared with in cells expressing BRCA1 or/and BRCA2 shRNAs only. These results suggested that Aur A/B and BRCA1/2 may function as antagonists to inversely regulate the cell proliferation and colony formation, and that the effect of Aur A/B and BRCA1/2 on the cell proliferation and colony formation may be enhanced by the concurrent disruption of homologous partner proteins, but may be offset by the depletion of counterpart proteins.
Converse control of cell cycle progression by Aur A/B and BRCA1/2
To validate the cell cycle alteration induced by the interruption of Aur A/B and BRCA1/2, we tested the major proteins involved in cell cycle regulation by Western blotting. Compared with in Capan-1-Scr (control) cells, the silencing of Aur A or Aur B enhanced the expression of p53, and attenuated the expressions of CDK6, cyclins D1, E, A, and B1 (Figure 4C). The concurrent silencing of Aur A and Aur B up-regulated the p53 expression, down-regulated the levels of CDK6, cyclins D1, E, and A, but enhanced the CDK4 and cyclin B1 expressions. The interruption of BRCA1 in Capan-1 cells decreased the expressions of p53, CDK6, cyclins D1, E, and B1 compared with in control cells. The disruption of both BRCA1 and Aur B blocked the expressions of p53 and cyclin B1, while lifted the expressions of CDK4, CDK6, CDK2, cyclins D1, E, and A in the resulting cells, compared with in cells expressing Aur B shRNA alone. However, the depletion of BRCA1 in Capan-1-Aur Ai-Aur Bi cells elevated the expressions of CDK6, but dropped the expressions of p53, cyclins D1, E, and B1 in Capan-1-Aur Ai-Aur Bi-BRCA1i cells. Collectively, the knockdown of Aur A/B mainly promoted the p53 expression but lessened the levels of most CDKs and cyclins to restrain the cell cycle progression of Capan-1 cells, while the disruption of BRCA1 inhibited p53 to promote the cell cycle progression.
The effects by the knockdown of Aur A/B or/and BRCA1/2 on the expressions of above proteins in OVCA433 cells (Figure 4D) were similar to those in Capan-1 cells. Compared with in OVCA433-Scr cells, the silencing of Aur A lifted the levels of p53, CDK4, cyclin E, but reduced the levels of cyclins A and B1 in OVCA433-Aur Ai cells. The silencing of Aur B promoted the expressions of p53, CDK4, CDK6, CDK2, and cyclin B1, but inhibited the expression of cyclin A in OVCA433-Aur Bi cells. Further silencing of Aur B in OVCA433-Aur Ai cells strengthened the levels of p53, CDK4, and cyclin E and B1, but largely reduced the levels of CDK6 in OVCA433-Aur Ai-Aur Bi cells. On the other hand, compared with in OVCA433-Scr cells, the depletion of BRCA1 did not alter the p53 expression, but up-regulated the CDK4 expression in OVCA433-BRCA1i cells. Further deleting of BRCA2 in OVCA433-BRCA1i cells increased the cyclin E expression, but slightly decreased the cyclin B1 expression the levels of p53, CDK4, CDK6, cyclin D1, and cyclin A were not conceivably changed. However, the disruption of Aur A in OVCA433-BRCA1i-BRCA2i cells enhanced the levels of p53, CDK4, CDK6, cyclin D1, CDK2, and cyclin B1, but blocked the expressions of cyclins E and A. The knockdown of Aur B in OVCA433-BRCA1i-BRCA2i cells diminished the levels of CDK4, CDK6, CDK2, cyclins D1, E, and A, but did not alter the level of p53. Moreover, the concurrent depletion of Aur A and B in OVCA433-BRCA1i-BRCA2i cells reduced the levels of CDK4, CDK6, CDK2, cyclin D1, E and A, which converted the changes of these proteins, suggesting that these proteins may be regulated by the interplay between Aur A/B and BRCA1/2.
To sum up, the expression of the cell cycle regulatory proteins including p53, CDK4, CDK6, cyclin D1, CDK2, cyclin E, cyclin B1, and cyclin A could be effectively regulated by Aur A/B and BRCA1/2 to control the cell cycle progression, and Aur A/B and BRCA1/2 may modulate the cell cycle fundamentally through p53 and cyclin A.
Counter impacts of Aur A/B and BRCA1/2 on cell multinuclearity and tetraploidy
Abscission is the last step of cytokinesis and the restrained abscission causes cytokinesis failure, resulting in cells with the multinuclearity and tetraploidy. Since Aur A/B and BRCA1/2 have been reported to be accumulated at midbody during the cytokinesis of late mitosis [4, 5, 22, 23], we detected these proteins by immunofluorescence. As shown in Figure 5C, both Aur A and Aur B were localized at the midbody during the late telophase in Capan-1 cells, but only a few of BRCA1 protein was observed at the midbody. The diminution of Aur A or BRCA1 slightly increased the expression of Aur B at the midbody. Aur A/B and BRCA1/2 co-localized at the midbody during the late telophase, but the staining of BRCA1 was faint in OVCA433 cells. The interruption of Aur A/B enhanced the BRCA2 accumulation at the midbody, but did not conceivably modify the staining of BRCA1. On the other hand, the revoking of BRCA2 following the BRCA1 knockdown dramatically enhanced the Aur A/B accumulation at the midbody (Figure 5D). Thus, Aur A/B and BRCA2 may inversely regulate cytokinesis to control the cell tetraploidization.
Aur A/B and BRCA1/2 mediate cell polyploidy
Diploidy cells (%)
Tetraploidy cells (%)
78.6 ± 3.2
16.2 ± 3.3
82.3 ± 3.9 (*S↑)
11.6 ± 5.1 (*S↓)
87.3 ± 5.9 (*S↑)
10.6 ± 4.6 (*S↓)
72.8 ± 6.1 (*S↓)
22.3 ± 6.4 (*S↑)
Aur Ai-Aur Bi
89.0 ± 4.7 (*S↑)
6.4 ± 3.9 (*S↓)
83.4 ± 5.0 (*S↑)
9.3 ± 6.7 (*S↓)
Aur Ai-Aur Bi-BRCA1i
78.0 ± 4.8 (*AB↓)
10.0 ± 4.7 (*AB↑)
88.9 ± 4.5
11.1 ± 4.5
95.0 ± 5.0 (*S↑)
5.0 ± 5.0 (*S↓)
95.0 ± 2.1 (*S↑)
5.0 ± 2.1 (*S↓)
80.0 ± 6.3 (*S↓)
20.0 ± 6.3 (*S↑)
Aur Ai-Aur Bi
97.8 ± 2.4 (*S↑)
2.2 ± 2.4 (*S↓)
77.8 ± 6.1 (*S↓)
22.2 ± 6.1 (*S↑)
90.0 ± 4.2 (*B1B2↑)
10.0 ± 4.2 (*B1B2↓)
84.6 ± 4.7 (*B1B2↑)
14.4 ± 4.9 (*B1B2↓)
BRCA1i-BRCA2i-Aur Ai-Aur Bi
91.2 ± 4.8 (*B1B2↑)
7.8 ± 5.6 (*B1B2↓)
Opposite function of Aur A/B and BRCA1-2 in tumorigenesis
The control of cell cycle in normal cells plays a key role in maintaining genetic fidelity during cell division. Any errors occurred during cell cycle progression may cause chromosome abnormalities, leading to cell aneuploidy or polyploidy, and subsequent tumorigenesis. It has been reported that the elevated Aur A promotes G1-S and G2-M transition , while silencing of Aur B results in acute cell cycle arrest in G1 phase . Phosphorylation of BRCA1 at S308 by Aur A in the M phase is an early event necessary for G2-M transition . Loss of BRCA1/2 leads to override of M phase, multinucleation and tetraploidy/polyploidy [9, 10]. We showed that, in this study, the silencing of Aur A/B suppressed overall cell cycle progression mainly through G1-S and G2-M transition, while the disruption of BRCA1/2 mainly promoted cell cycle progression through accelerated G1-S and G2-M transition, suggesting that Aur A/B and BRCA1/2 negatively regulate G1-S and G2-M transitions to control cell cycle progression. Furthermore, we found that the expression of p53 was negatively regulated by Aur A/B, but positively regulated by BRCA1/2, which was consistent with previous studies [25, 26], indicating that p53 might be the focused target of both Aur A/B and BRCA1/2 through which to modulate cell cycle progression and tetraploidization. Moreover, studies have shown that cyclin A is essential for the G1-S and G2-M transitions , and that cyclin A availability is the rate-limiting step for entry into mitosis . We found that the disruption of Aur A/B down-regulated cyclin A expression, but the silencing of BRCA1/2 up-regulated cyclin A. Therefore, cyclin A may be another mediator regulated conversely by Aur A/B and BRCA1/2 to control cell proliferation, cell cycle progression, and tumorigenesis.
Complete mitosis is composed of nuclei division and cytoplasm separation - cytokinesis. The last step of cytokinesis is the abscission of midbody, the failure of which is associated with delayed cytokinesis and ploidy changes . Inactivation of Aur B promotes completion of cytokinesis by abscission to suppress tetraploidization . BRCA2 interacts with many abscission factors at the midbody, and the disruption of these abscission factors results in increased cytokinetic defects . We previously reported that Aur A inversely regulates BRCA2 at the midbody during cytokinesis to promote polyploidy . In this study, we showed that Aur A/B and BRCA2 were co-localized at midbody and conversely regulated the counterparts during late mitosis, indicating that the interplay of Aur A/B and BRCA2 may manipulate cytokinesis to keep a proper segregation of two daughter cells from polyploidy. Additionally, as reported, although no BRCA1 staining was observed at the midbody in immunofluorescence slides of cervical cancer cells HeLa , evident localization of BRCA1 was found in the midbody area during cytokinesis in immunoelectron-microscopic sections of breast cancer cells SKBR3 . In this study, the staining of BRCA1 at the midbody of mitotic Capan-1 cells was not strong, and the knockdown of Aur A/B did not fortify the accumulation of BRCA1 at the midbody, indicating that the role of BRCA1 at the midbody may be less valuable. However, we did find that the silencing of BRCA1 promoted cell tetraploidization, indicating that BRCA1 may regulate tetraploid through a different way, for example the regulation of centrosome. More importantly, the concurrent silencing of Aur A, Aur B, BRCA1, and BRCA2 did not induce complete cytokinesis failure in both Capan-1 and OVCA433 cells, implying that some other factors such as survivin and HIPK2 It is well-known that the proteasome-mediated degradation may still function to maintain cytokinesis [31, 32].
Is one of the possible mechanisms in the post-translation regulation proteins. The mounting studies have evidenced that the expression levels of Aur A/B and BRCA1/2 may be also controlled through ubiquitin-mediated protein degradation. For instances, FBXW7, a component of E3 ubiquitin ligase, can target both Aur A and Aur B for ubiquitination and subsequent degradation [18, 19]. BRCA1 forms a heterodimer with BRCA1-associated RING domain 1 (BARD1) and exhibits the E3 ubiquitin ligase activity to target other proteins , while the Aur A kinase functions to inhibit the E3 ubiquitin ligase activity of BRCA1 . Moreover, BRCA1/2 may interact with Aur B through the BRCA1-associated ring domain protein 1 (BARD1) to modulate the mitotic spindle formation, cytokinesis, aneuploidy and genomic instability . BARD1β, an isoform of BARD1 deficient of RING domain, stabilizes Aur B and forms a complex with BRCA2 and Aur B . In this study, by qRT-PCR and cell treatment with MG132, we showed that the interactive regulation of protein expressions between Aur A/B and BRCA1/2 was mainly controlled through the proteasome-mediated proteolysis although the detailed mechanism may need more investigations.
In conclusion, the interplay of Aur A/B and BRCA1/2 constitutes a regulatory network in cancer development. A schematic diagram in Additional file 2: Figure S1 is to illustrate that Aur A/B and BRCA1/2 were negatively regulated between each other likely through proteasome-mediated proteolysis (PMP) to control cell proliferation, cell cycle progression, cytokinesis, tetraploid, and eventually tumorigenesis of cancer cells. Molecules including p53 and cyclin A may be the major mediators inversely regulated by imbalanced expressions of Aur A/B and BRCA1/2 in cancer cells. Although the interactive regulation between Aur A/B and BRCA1/2 may lie in different pathways such as proteolysis as we reported , this study may have provided some novel insights that the negative interplay between Aur A/B and BRCA1/2 plays an essential role during cancer development. The results of this study may be used to improve the efficacy of the current therapeutic methods in cancers specifically with amplified Aur A/B and inactivated BRCA1/2.
This work was supported by Doctoral Fund of Ministry of Education of China (20120071110079), by National Nature Science Foundation of China (91129721 and 81372797), by Shanghai Pujiang Program (11PJ1402200) from Shanghai Municipal Government of China, and by the key project of Shanghai Municipal Health Bureau (20114009) for G. Yang; and by National Nature Science Foundation of China (81372432) for Z. Zhang.
- Marumoto T, Zhang D, Saya H: Aurora-A - a guardian of poles. Nat Rev Cancer. 2005, 5: 42-50. 10.1038/nrc1526View ArticlePubMedGoogle Scholar
- Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J: Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 2010, 16: 3171-3181. 10.1158/1078-0432.CCR-09-3171PubMed CentralView ArticlePubMedGoogle Scholar
- Song J, Salek-Ardakani S, So T, Croft M: The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol. 2007, 8: 64-73. 10.1038/ni1413View ArticlePubMedGoogle Scholar
- Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih Ie M, Wong KK, Gershenson DM, Liu J: RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer. 2013, 133: 275-285. 10.1002/ijc.28032View ArticlePubMedGoogle Scholar
- Steigemann P, Wurzenberger C, Schmitz MH, Held M, Guizetti J, Maar S, Gerlich DW: Aurora B-mediated abscission checkpoint protects against tetraploidization. Cell. 2009, 136: 473-484. 10.1016/j.cell.2008.12.020View ArticlePubMedGoogle Scholar
- Shabbeer S, Omer D, Berneman D, Weitzman O, Alpaugh A, Pietraszkiewicz A, Metsuyanim S, Shainskaya A, Papa MZ, Yarden RI: BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation. Oncogene. 2012, 32: 5005-5016.PubMed CentralView ArticlePubMedGoogle Scholar
- Misra S, Sharma S, Agarwal A, Khedkar SV, Tripathi MK, Mittal MK, Chaudhuri G: Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells. Mol Cancer. 2010, 9: 50- 10.1186/1476-4598-9-50PubMed CentralView ArticlePubMedGoogle Scholar
- Schuldt A: Cell cycle. A complex twist for BRCA2. Nat Rev Mol Cell Biol. 2001, 2: 164-View ArticlePubMedGoogle Scholar
- Yu VM, Marion CM, Austria TM, Yeh J, Schonthal AH, Dubeau L: Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. Int J Cancer. 2012, 130: 2495-2504. 10.1002/ijc.26309PubMed CentralView ArticlePubMedGoogle Scholar
- Jonsdottir AB, Stefansson OA, Bjornsson J, Jonasson JG, Ogmundsdottir HM, Eyfjord JE: Tetraploidy in BRCA2 breast tumours. Eur J Cancer. 2012, 48: 305-310.View ArticlePubMedGoogle Scholar
- Schlegel BP, Starita LM, Parvin JD: Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells. Oncogene. 2003, 22: 983-991. 10.1038/sj.onc.1206195View ArticlePubMedGoogle Scholar
- Daniels MJ, Wang Y, Lee M, Venkitaraman AR: Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science. 2004, 306: 876-879. 10.1126/science.1102574View ArticlePubMedGoogle Scholar
- Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T: BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem. 2004, 279: 19643-19648. 10.1074/jbc.M311780200View ArticlePubMedGoogle Scholar
- Shao S, Wang Y, Jin S, Song Y, Wang X, Fan W, Zhao Z, Fu M, Tong T, Dong L, Fan F, Xu N, Zhan Q: Gadd45a interacts with aurora-A and inhibits its kinase activity. J Biol Chem. 2006, 281: 28943-28950. 10.1074/jbc.M600235200View ArticlePubMedGoogle Scholar
- Sagulenko E, Savelyeva L, Ehemann V, Sagulenko V, Hofmann W, Arnold K, Claas A, Scherneck S, Schwab M: Suppression of polyploidy by the BRCA2 protein. Cancer Lett. 2007, 257: 65-72. 10.1016/j.canlet.2007.07.003View ArticlePubMedGoogle Scholar
- Wang Z, Hou J, Lu L, Qi Z, Sun J, Gao W, Meng J, Wang Y, Sun H, Gu H, Xin Y, Guo X, Yang G: Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways. PLoS One. 2013, 8: e79117- 10.1371/journal.pone.0079117PubMed CentralView ArticlePubMedGoogle Scholar
- Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 2010, 102: 812-827. 10.1093/jnci/djq127PubMed CentralView ArticlePubMedGoogle Scholar
- Kwon YW, Kim IJ, Wu D, Lu J, Stock WA, Liu Y, Huang Y, Kang HC, DelRosario R, Jen KY, Perez-Losada J, Wei G, Balmain A, Mao J-H: Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res. 2012, 10: 834-844. 10.1158/1541-7786.MCR-12-0025PubMed CentralView ArticlePubMedGoogle Scholar
- Teng CL, Hsieh YC, Phan L, Shin J, Gully C, Velazquez-Torres G, Skerl S, Yeung SC, Hsu SL, Lee MH: FBXW7 is involved in Aurora B degradation. Cell Cycle. 2012, 11: 4059-4068. 10.4161/cc.22381PubMed CentralView ArticlePubMedGoogle Scholar
- Malone JL, Nelson AC, Lieberman R, Anderson S, Holt JT: Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast. J Pathol. 2009, 217: 380-388. 10.1002/path.2458PubMed CentralView ArticlePubMedGoogle Scholar
- Choi YH: Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells. Int J Oncol. 2001, 19: 687-693.PubMedGoogle Scholar
- Mondal G, Rowley M, Guidugli L, Wu J, Pankratz VS, Couch FJ: BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev Cell. 2012, 23: 137-152. 10.1016/j.devcel.2012.05.008PubMed CentralView ArticlePubMedGoogle Scholar
- Lotti LV, Ottini L, D’Amico C, Gradini R, Cama A, Belleudi F, Frati L, Torrisi MR, Mariani-Costantini R: Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer. 2002, 35: 193-203. 10.1002/gcc.10105View ArticlePubMedGoogle Scholar
- Kumari G, Ulrich T, Gaubatz S: A role for p38 in transcriptional elongation of p21 (CIP1) in response to Aurora B inhibition. Cell Cycle. 2013, 12: 2051-2060. 10.4161/cc.25100PubMed CentralView ArticlePubMedGoogle Scholar
- Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004, 36: 55-62. 10.1038/ng1279View ArticlePubMedGoogle Scholar
- Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, Guma S, Phan L, Chou P-C, Su C-H, Zhang F, Chen J-S, Yang T-Y, Yeung S-CJ, Lee M-H: Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A. 2012, 109: E1513-E1522. 10.1073/pnas.1110287109PubMed CentralView ArticlePubMedGoogle Scholar
- Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J. 1992, 11: 961-971.PubMed CentralPubMedGoogle Scholar
- Yoshizumi M, Lee WS, Hsieh CM, Tsai JC, Li J, Perrella MA, Patterson C, Endege WO, Schlegel R, Lee ME: Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest. 1995, 95: 2275-2280. 10.1172/JCI117918PubMed CentralView ArticlePubMedGoogle Scholar
- Singh U, Westermark B: CGGBP1 is a nuclear and midbody protein regulating abscission. Exp Cell Res. 2011, 317: 143-150. 10.1016/j.yexcr.2010.08.019View ArticlePubMedGoogle Scholar
- Ryser S, Dizin E, Jefford CE, Delaval B, Gagos S, Christodoulidou A, Krause KH, Birnbaum D, Irminger-Finger I: Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res. 2009, 69: 1125-1134. 10.1158/0008-5472.CAN-08-2134View ArticlePubMedGoogle Scholar
- Altieri DC: Cytokinesis, apoptosis and survivin: three for tango?. Cell Death Differ. 2001, 8: 4-5. 10.1038/sj.cdd.4400795View ArticlePubMedGoogle Scholar
- Rinaldo C, Moncada A, Gradi A, Ciuffini L, D’Eliseo D, Siepi F, Prodosmo A, Giorgi A, Pierantoni GM, Trapasso F, Guarguaglini G, Bartolazzi A, Cundari E, Schininà ME, Fusco A, Soddu S: HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell. 2012, 47: 87-98.View ArticlePubMedGoogle Scholar
- Xia Y, Pao GM, Chen HW, Verma IM, Hunter T: Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem. 2003, 278: 5255-5263. 10.1074/jbc.M204591200View ArticlePubMedGoogle Scholar
- Sankaran S, Crone DE, Palazzo RE, Parvin JD: Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Res. 2007, 67: 11186-11194. 10.1158/0008-5472.CAN-07-2578View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.